326. Osteopetrosis Clinical trials / Disease details


Clinical trials : 20 Drugs : 51 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 81

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02666768
(ClinicalTrials.gov)
February 22, 201623/6/2015ACTIMMUNE in Intermediate OsteopetrosisOpen-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of OsteopetrosisOsteopetrosisDrug: Interferon gamma-1bLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterUniversity of Minnesota;Horizon Pharma Ireland, Ltd., Dublin IrelandCompleted1 YearN/AAll5Phase 2United States
2NCT02584608
(ClinicalTrials.gov)
January 1, 201620/10/2015Use of ACTIMMUNE in Patients With ADO2Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 OsteopetrosisAutosomal Dominant Osteopetrosis Type 2Drug: ACTIMMUNEIndiana UniversityHorizon Pharma Ireland, Ltd., Dublin IrelandCompleted3 Years65 YearsAll12Phase 2United States
3NCT00043329
(ClinicalTrials.gov)
January 20027/8/2002Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant OsteopetrosisPost-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant OsteopetrosisOsteopetrosisDrug: Actimmune RegistryInterMuneNULLCompletedN/AN/ABoth6United States